Shares of biopharma Versartis (NASDAQ: VSAR) crashed nearly 87% Friday after somavaratan, the company’s lead drug candidate, did not meet its primary endpoint in the phase 3 Velocity trial. The drug is a recombinant human growth hormone that was being evaluated as a treatment for growth hormone deficiency in children. It failed to spur height growth as well as Genotropin from Pfizer, the current standard treatment.